Leerink Partnrs Has Bearish Outlook for KYTX FY2025 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Kyverna Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.66) per share for the year, down from their prior forecast of ($3.63). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2025 earnings at ($0.82) EPS, FY2026 earnings at ($3.27) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($3.97) EPS and FY2029 earnings at ($3.26) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.12.

A number of other equities analysts also recently commented on the stock. William Blair started coverage on shares of Kyverna Therapeutics in a report on Wednesday, August 20th. They issued an “outperform” rating for the company. Wells Fargo & Company raised their price target on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. HC Wainwright boosted their price objective on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Kyverna Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $23.67.

Kyverna Therapeutics Price Performance

Shares of NASDAQ KYTX opened at $7.16 on Monday. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $8.45. The business has a fifty day moving average price of $6.27 and a 200 day moving average price of $4.28. The stock has a market capitalization of $313.61 million, a P/E ratio of -1.92 and a beta of 3.78.

Institutional Trading of Kyverna Therapeutics

Institutional investors have recently bought and sold shares of the stock. Woodline Partners LP purchased a new stake in Kyverna Therapeutics during the 3rd quarter worth approximately $1,513,000. TD Asset Management Inc lifted its stake in shares of Kyverna Therapeutics by 179.5% during the second quarter. TD Asset Management Inc now owns 252,196 shares of the company’s stock worth $774,000 after buying an additional 161,954 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Kyverna Therapeutics during the third quarter valued at $886,000. Bridgeway Capital Management LLC grew its holdings in shares of Kyverna Therapeutics by 178.1% during the third quarter. Bridgeway Capital Management LLC now owns 174,900 shares of the company’s stock valued at $1,049,000 after buying an additional 112,000 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Kyverna Therapeutics by 21.9% in the 3rd quarter. Millennium Management LLC now owns 551,635 shares of the company’s stock valued at $3,310,000 after acquiring an additional 99,075 shares during the period. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.